COVID-19

IMUNON Files IND Application to Begin Human Testing of IMNN-101

Company expects enrollment in Phase 1 proof-of-concept study of DNA-based vaccine technology to begin in Q2The application follows guidance provided…

4 months ago

Hyperfine, Inc. Collaborates with King’s College London to Demonstrate the Swoop® System and UNITY Project to The Princess Royal

The Princess Royal was introduced to the first FDA-cleared portable MR brain imaging system being used to test the disparities…

4 months ago

Zomedica Announces Sponsorship of Educational Presentations at Fetch dvm360 Veterinary Conferences

ANN ARBOR, MI / ACCESSWIRE / March 12, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary…

4 months ago

Nanox Announces AI Software Increases Identification of Patients with Vertebral Compression Fractures, an early sign of Osteoporosis, Up to Six-Fold

– According to early findings in the ADOPT study, Nanox.AI software improves detection of key risk factor for osteoporosis, outperforming…

4 months ago

Roche Annual General Meeting 2024

All proposals of the Board of Directors approvedSeverin Schwan re-elected as Chairman of the Board of Directors; all other Board…

4 months ago

Mainz Biomed Presents ColoAlert® at UDH Congress 2024: Leading the Way in Evidence-Based Cancer Screening Innovations

BERKELEY, Calif. and MAINZ, Germany, March 12, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”),…

4 months ago

Immunovant Awarded U.S. Patent for IMVT-1402

Composition of matter patent issued with coverage until June 2043Patent also includes methods of use and methods of manufacturing claims…

4 months ago

SIGA Declares Special Cash Dividend of $0.60 Per Share

Represents a $0.15 Per Share Increase Over 2023 Special DividendNEW YORK, March 12, 2024 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc.…

4 months ago

Bioventus Announces Fourth Quarter and Full Year 2023 Financial Results

Accelerated fourth quarter sales growth to 7.6%, organic growth* of 14.3%Appointed Rob Claypoole as President and Chief Executive Officer, bringing…

4 months ago

Revive Therapeutics Provides Corporate Update

TORONTO, March 12, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a…

4 months ago